New treatment for advanced ovarian cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a drug called mirvetuximab soravtansine for people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer that has high levels of a protein called folate receptor-alpha (FRα). It is given through a vein (IV) and aims to stop cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced ovarian, peritoneal, or fallopian tube cancer that is high-grade serous type.
- Your cancer must be resistant to platinum-based chemotherapy.
- You must have at least one tumor that can be measured on a scan.
- Your tumor must have high levels of folate receptor-alpha (FRα) (at least 75% of cells staining moderately).
- You must be well enough to perform daily activities (ECOG score 0 or 1).
- You must not have had a stroke in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
This study tests a drug called mirvetuximab soravtansine (MIRV) for women with ovarian, fallopian tube, or primary peritoneal cancer that has not responded to recent treatment. The drug targets a specific protein (FRα) found on some cancer cells, and the study will see how well it works in real-world settings.
This Phase 2 study tests adding mirvetuximab to carboplatin for people with advanced, high-grade serous ovarian cancer who will first receive “neoadjuvant” chemotherapy. It is designed for tumors that strongly show FRα, which mirvetuximab targets, to see if this improves outcomes.
This trial tests a new drug combination (torvutatug samrotecan plus bevacizumab) as maintenance therapy to help keep advanced ovarian cancer from growing after initial chemotherapy. It is for people whose tumors do not have a specific genetic change called HRD.
This study is testing a drug called mirvetuximab soravtansine (MIRV) in real-world conditions for people with a specific type of ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see how well the drug works and what side effects occur in everyday practice.
This study tests a new combination of two medications for ovarian cancer that has stopped responding to standard platinum-based chemotherapy. The goal is to see if this combo can shrink tumors or slow the disease down in patients who have limited options left.
Hear when a new Primary Peritoneal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.